Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

SCI (Stem Cell Innovations) forms pact to explore bone-forming capacity of Pluricells:

This article was originally published in Clinica

  • News

Executive Summary

US firm Stem Cell Innovations (SCI) has linked up with the University of Twente, in Enschede, the Netherlands, to assess the bone-forming properties of its PluriCells, a type of pluripotent stem cells isolated from foetal tissue. Houston, Texas-based SCI will give the university access to its human pluripotent stem cell technology and know-how in return for a nonexclusive licence to intellectual property generated with the PluriCells. PluriCells are developed from foetal germ cells rather than viable embryos and are, therefore, excluded from the US 2002 ban on federally funded stem cell research.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

See All
UsernamePublicRestriction

Register

MT053223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By